Our company leveraged over 20 years of advanced research on natural antiviral compounds which uncovered the formulation found in CROWN/ARMOR. This particular bioactive formulation was found to be a preventative to many virus strains, including coronaviruses
Multiple published research studies revealed the CROWN/ARMOR spray product to be both virucidal and antiviral, decreasing the infectivity and transmissivity of multiple strains of viruses in vivo and in vitro.
In one independent in vitro study, CROWN/ARMOR was tested on the coronavirus that caused SARS and showed significant virucidal activity. It was found that applying CROWN/ARMOR to a mask prevented the virus from penetrating with a 99.9, efficacy rate.
OUR LATEST CASE STUDIES
Summary of Studies:
The composition of CrownArmor spray was invented by our Chief Medical Adviser and has undergone extensive scientific study by leading University research laboratories worldwide.
In cell culture model systems, the formulation had significant in vitro activity against influenza virus H3N2 at concentrations that were not associated with significant cellular toxic effects.
No adverse events were associated with administration of the compound intranasally to ferrets.
No adverse events seen in chickens with formulation in food, water or as a nasal spray at three difference concentrations.
The antiviral activities of the formulation were examined for influenza virus H3N2 by means of an assay based on Madin-Darby canine kidney cells. The formulation was able to completely eradicate H3N2 from the cell culture system. Masks impregnated with product were highly effective in blocking the passage of live H3N2 virus. Two different in vitro models showed virucidal activity of the compound against a corona virus, avian infectious bronchitis virus (IBV).
In vivo animal model, ferrets
The formulation was tested against the two influenza A H3N2 viruses in the ferret model, using several different exposure scenarios including nasal inoculation or via spreading from infected animals to uninfected counterparts. Effects of the formulation on seroconversion, virus shedding, and systemic sequelae of infection were evaluated. The studies showed that the compound prevented transmission and provided prophylaxis against influenza virus H3N2. Prophylaxis with the formulation was significantly more than with oseltamivir, the active ingredient in Tamiflu.
In vivo animal model, chickens
Administering the formulation to chickens by spray before challenge with IBV decreased the severity of clinical signs and lesions in the birds, and lowered the amount of viral RNA in the
trachea. Treatment with the formulation protected chickens for up to 4 days post-treatment from clinical signs of disease (but not from infection) and decreased transmission of IBV over a 14-day period. Anti-IBV activity was greater prior to virus attachment and entry indicating that the effect is virucidal. In addition, the formulation had activity against both Massachusetts and Arkansas type IB viruses, indicating that it can be expected to be effective against IBV regardless of
- Choosing a selection results in a full page refresh.
- Press the space key then arrow keys to make a selection.